Here you can see and modify the cookie settings of various tools used on and related subdomains.

Save settings
Advantage Austria Show navigation

Apeiron nominated for prestigious biotechnology prize

Medical Industry © Advantage Austria © ADVANTAGE AUSTRIA


28. August 2010

Vienna-based biotech company Apeiron Biologics AG has been nominated as one of three finalists for the European Biotechnica Award. The Biotechnica Award, which is presented by Deutsche Messe AG as part of the sector's leading trade fair, is regarded as Europe's most prestigious biotech award. Apeiron is the only unlisted finalist.  

The Vienna-based biotech company APEIRON Biologics AG has been nominated as one of three finalists for the European Biotechnica Award. Apeiron first caught the attention of industry insiders in January 2010 when it signed a licensing agreement with GlaxoSmithKline (GSK) valued at EUR 236 million for the rights to Apeiron s lead product APN01.
The European Biotechnica Award is the most important prize of its kind in Europe, and is aimed at European-based companies working in biotechnology and the life sciences who have developed particularly innovative products, services and associated business ideas. The award ceremony will take place on 4 October 2010 at the opening of BIOTECHNICA in Hannover.

European Biotechnica Award © Deutsche Messe


Just six months ago, a licensing agreement with a total deal volume of around  EUR 236 million was signed for the lead product APN01, a drug candidate for treatment of Acute Respiratory Distress Syndrome (ARDS). This agreement with GSK was the starting point for the expansion of the company's development pipeline, focussing on the field of biological and immunological cancer therapies. As Dr. Hans Loibner, CEO of Apeiron states: "The licensing deal with GSK has contributed substantially to strengthening Apeiron's financial base. As such, we are now able to diversify our pipeline, both through in-house projects, as well as by licensing-in more established clinical projects. The nomination by the jury of the European Biotechnica Award has confirmed to us and to potential licensing partners that the path Apeiron has taken is the right one. It goes without saying that we are very pleased about this nomination!"


Together with Apeiron, Addex Pharmaceuticals from Switzerland and Galapagos Genomics from Belgium qualified for the final round this year. In contrast to Apeiron, both other companies are listed on stock exchanges. This is something that makes Apeiron's nomination particularly interesting to investors. In connection with the GSK deal, Apeiron stunned industry experts when the company disclosed that professional development of the then licensed-out lead product had been carried out from basic research until completion of the first clinical phase without venture capital and involving a total sum of no more than around EUR 6.5 million.

About Apeiron

Apeiron Biologics AG is a privately financed Biotech company based in Vienna. In February 2010, the then lead product APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme-based bio-therapeutic for treatment of Acute Respiratory Distress Syndrome (ARDS) and a series of other diseases, was licensed out to GSK in a milestone-based agreement for approx. EUR 236 million. Currently, building on an existing set of innovative in-house projects, Apeiron is expanding its portfolio with clinical projects up to Phase II with a focus on biologic / immunologic therapy of cancer. Apeiron employs 15 members of staff at its main site, the Campus Vienna Biocenter.